Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie Doubles Down In IBD With Skyrizi Ulcerative Colitis Approval

Jun 20 2024

• By Kevin Grogan

• Source: Shutterstock

Related Content

AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis

Mar 23 2023

Lilly Plans Mirikizumab Filing For Crohn’s After Phase III Success

Oct 12 2023

AbbVie Ups Efforts In HS And Advances Lutikizumab Into Phase III

Jan 09 2024

AbbVie Adds IBD Candidate In Deal With China’s FutureGen

Jun 13 2024

AbbVie's Skyrizi Adds Crohn's Disease Indication In Europe

Nov 23 2022

Related Companies

AbbVie Inc.

Johnson & Johnson

Eli Lilly and Company

FutureGen Biopharmaceutical (Beijing) Co., Ltd.

Additional Topics

Approvals Business Strategies Drug Review FDA Regulatory Gastrointestinal Immune Disorders Inflammation BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.